MCID: BLD007
MIFTS: 14

Bile Duct Signet Ring Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Signet Ring Cell Carcinoma

MalaCards integrated aliases for Bile Duct Signet Ring Cell Carcinoma:

Name: Bile Duct Signet Ring Cell Carcinoma 12
Extrahepatic Bile Duct Signet Ring Cell Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3494
NCIt 47 C5776
UMLS 69 C0861859

Summaries for Bile Duct Signet Ring Cell Carcinoma

MalaCards based summary : Bile Duct Signet Ring Cell Carcinoma, is also known as extrahepatic bile duct signet ring cell carcinoma, and has symptoms including abdominal pain, icterus and nausea. The drugs Pancrelipase and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver.

Related Diseases for Bile Duct Signet Ring Cell Carcinoma

Symptoms & Phenotypes for Bile Duct Signet Ring Cell Carcinoma

UMLS symptoms related to Bile Duct Signet Ring Cell Carcinoma:


abdominal pain, icterus, nausea, pruritus, vomiting, malaise

Drugs & Therapeutics for Bile Duct Signet Ring Cell Carcinoma

Drugs for Bile Duct Signet Ring Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 1 53608-75-6
2
Fluorouracil Approved Phase 1 51-21-8 3385
3
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
4
Levoleucovorin Approved Phase 1 68538-85-2
5
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 43805 6857599
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
8
Camptothecin Experimental Phase 1 7689-03-4
9 Antibodies Phase 1
10 Immunoglobulins Phase 1
11 Liver Extracts Phase 1
12 pancreatin Phase 1
13 Antidotes Phase 1
14 Antimetabolites Phase 1
15 Antimetabolites, Antineoplastic Phase 1
16 Antineoplastic Agents, Phytogenic Phase 1
17 Calcium, Dietary Phase 1
18 Immunosuppressive Agents Phase 1
19 Micronutrients Phase 1
20 Protective Agents Phase 1
21 topoisomerase I inhibitors Phase 1
22 Topoisomerase Inhibitors Phase 1
23 Trace Elements Phase 1
24 Vitamin B Complex Phase 1
25 Vitamins Phase 1
26 Cola Nutraceutical Phase 1
27 Folate Nutraceutical Phase 1
28 Vitamin B9 Nutraceutical Phase 1

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
2 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil

Search NIH Clinical Center for Bile Duct Signet Ring Cell Carcinoma

Genetic Tests for Bile Duct Signet Ring Cell Carcinoma

Anatomical Context for Bile Duct Signet Ring Cell Carcinoma

MalaCards organs/tissues related to Bile Duct Signet Ring Cell Carcinoma:

39
Liver

Publications for Bile Duct Signet Ring Cell Carcinoma

Articles related to Bile Duct Signet Ring Cell Carcinoma:

id Title Authors Year
1
Rapidly Progressing Primary Extrahepatic Bile Duct Signet-Ring Cell Carcinoma in a Caucasian Woman. ( 27270710 )
2016

Variations for Bile Duct Signet Ring Cell Carcinoma

Expression for Bile Duct Signet Ring Cell Carcinoma

Search GEO for disease gene expression data for Bile Duct Signet Ring Cell Carcinoma.

Pathways for Bile Duct Signet Ring Cell Carcinoma

GO Terms for Bile Duct Signet Ring Cell Carcinoma

Sources for Bile Duct Signet Ring Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....